

WEST PHARMACEUTICAL SERVICES INC
Form 8-K
May 08, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – May 7, 2013

WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction
of Incorporation)

1-8036
(Commission File Number)

23-1210010
(IRS Employer
Identification No.)

530 Herman O. West Drive, Exton,
PA
(Address of principal executive
offices)

19341-0645
(Zip Code)

Registrant's telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

Our 2013 Annual Meeting of Shareholders was held on May 7, 2013 at the Company's corporate headquarters. Our shareholders voted on three proposals at the Annual Meeting. The proposals are described in detail in our definitive proxy statement dated March 27, 2013. As of March 11, 2013, the record date, there were 34,612,051 shares outstanding. Shareholders representing 31,820,664 or 91.93%, of the common shares outstanding were present in person or were represented by proxy. The final results for the votes on each proposal are set forth below.

Proposal 1: Our shareholders elected the following directors to serve on our Board until the 2014 Annual Meeting of Shareholders.

| Name | For | Withheld | Broker Non-Votes |
|----------------------|------------|-----------|------------------|
| Mark A. Buthman | 29,836,060 | 33,623 | 1,950,981 |
| William F. Feehery | 29,841,746 | 27,937 | 1,950,981 |
| Thomas W. Hofmann | 29,832,267 | 37,416 | 1,950,981 |
| L. Robert Johnson | 29,797,357 | 72,326 | 1,950,981 |
| Paula A. Johnson | 29,844,971 | 24,712 | 1,950,981 |
| Douglas A. Michels | 29,841,646 | 28,037 | 1,950,981 |
| Donald E. Morel, Jr. | 29,095,547 | 774,136 | 1,950,981 |
| John H. Weiland | 29,357,584 | 512,099 | 1,950,981 |
| Anthony Welters | 28,718,098 | 1,151,585 | 1,950,981 |
| Patrick J. Zenner | 29,351,922 | 517,761 | 1,950,981 |

Proposal 2: Our shareholders approved, on an advisory basis, named executive officer compensation:

| For | Against | Abstain | Broker Non-Votes |
|------------|-----------|---------|------------------|
| 28,230,633 | 1,627,279 | 11,771 | 1,950,981 |

Proposal 3: Our shareholders ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2013 fiscal year. The votes regarding this proposal were as follows:

| For | Against | Abstain | Broker Non-Votes |
|------------|---------|---------|------------------|
| 31,110,283 | 703,531 | 6,850 | Not applicable |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES,
INC.

/s/ John R. Gailey III
John R. Gailey III, Senior Vice President,
General Counsel and Secretary

May 8, 2013